Rosenwald Discusses Success of Abiraterone Acetate

Abiraterone Acetate pic In a recent interview with CNN iReport, Dr. Lindsay Rosenwald discussed abiraterone acetate, a drug developed by Cougar Biotechnology that is one of the most promising cancer treatments available. The drug has demonstrated a significantly higher survival rate among patients with late-stage prostate cancer, and in trials, it has shown that it could benefit patients with advanced breast cancer. Rosenwald said the drug, which inhibits the growth of androgens that encourage cancer, is in on track to be a “multi-billion-dollar pharmaceutical.” Rosenwald is a co-founder and original financial backer of Cougar Biotechnology.

Marketed as Zytiga, abiraterone acetate has the potential to prolong or enhance the lives of thousands of people, Rosenwald said in the interview. As people live longer, they are exposed to more cancer-causing agents that require the development of alternative treatment options.

Zytiga was released to the market in 2011 after being tested on more than 1,200 patients with advanced prostate cancer. Cougar Biotechnology, which was acquired for more than $1 billion by Johnson & Johnson during clinical trials for abiraterone acetate, now operates as a subsidiary of the pharmaceutical giant.

Advertisements
Explore posts in the same categories: Lindsay Rosenwald, Pharmaceuticals

Tags: , ,

You can comment below, or link to this permanent URL from your own site.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: